In the report, Oppenheimer writes, “Overall, our investment bias in large cap remains toward companies focusing cash flow on diversification efforts and working more broadly/creatively with hospitals in an environment where providers want fewer vendors. We see Outperform-rated MDT and SYK as farther along in these efforts. We note that Perform-rated BSX and STJ have P&L offsets to near-term revenue pressures and expectations are low for both heading into 3Q.Medium-term overhangs keep us on the sidelines. Finally, we remain most cautious on Perform-rated ZMH given high exposure to the sluggish hip/knee market”.
Companies Included in the Oppenheimer report are: Medtronic MDT, Stryker SYK, Boston Scientific BSX, and St. Jude Medical STJ.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in